Home Products Most Popular Contact
No items in your cart.
The page below is a sample from the LabCE course Autism Spectrum Disorders: Genetic Testing [retired 4/9/2020]. Access the complete course and earn ASCLS P.A.C.E.-approved continuing education credits by subscribing online.

Learn more about Autism Spectrum Disorders: Genetic Testing [retired 4/9/2020] (online CE course) »
How to Subscribe
Individual course$20 Add to cart

Insurer's Coverage Recommendations on ASD Genetic Testing

Many major insurers, including several Blue Cross/Blue Shield affiliates, Aetna, and others consider CMA testing for ASD and other intellectual disabilities as medically necessary and recommend the use of CMA testing in the initial postnatal evaluation of individuals with multiple congenital anomalies, DD/ID, and ASD. It appears that this positive recommendation given by the insurers is in part based on the recommendations given by the professional societies as discussed in the previous section of this course.
Although many insurers consider CMA testing for ASD as medically necessary, a few insurers specifically consider the FirstStepDx PLUS® and other similar genetic testing for ASD as experimental and investigational. This is because the peer-reviewed medical literature does not support the use of these procedures and services in the assessment and treatment of autism and other pervasive developmental disorders.